Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2026-01-09

Clinical Trial Update: Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating panobinostat (LBH589) in patients with sickle cell disease is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Panobinostat (Panobinostat)

Snippet

Sponsor: Abdullah Kutlar | Conditions: Sickle Cell Disease | Phase 1 | Status: RECRUITING